Plus Stock Based Compensation from 2010 to 2025

Stocks . USA . 
Stock . Plus Therapeutics
PSTV Stock  USD 1.26  0.03  2.44%   
Plus Therapeutics Stock Based Compensation yearly trend continues to be fairly stable with very little volatility. Stock Based Compensation will likely drop to about 486.5 K in 2025. Stock Based Compensation is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. View All Fundamentals
 
Stock Based Compensation  
First Reported
2001-12-31
Previous Quarter
151 K
Current Value
125 K
Quarterly Volatility
555.4 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Plus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Plus Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 337.7 K, Selling General Administrative of 10.2 M or Selling And Marketing Expenses of 637 K, as well as many indicators such as Price To Sales Ratio of 1.22, Dividend Yield of 0.0022 or Days Sales Outstanding of 46.47. Plus financial statements analysis is a perfect complement when working with Plus Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Plus Therapeutics Correlation against competitors.
For more information on how to buy Plus Stock please use our How to Invest in Plus Therapeutics guide.

Latest Plus Therapeutics' Stock Based Compensation Growth Pattern

Below is the plot of the Stock Based Compensation of Plus Therapeutics over the last few years. It is compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders. Plus Therapeutics' Stock Based Compensation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Plus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Stock Based Compensation10 Years Trend
Slightly volatile
Compare to OthersAll Fundamentals
   Stock Based Compensation   
       Timeline  

Plus Stock Based Compensation Regression Statistics

Arithmetic Mean72,394,475
Geometric Mean1,372,448
Coefficient Of Variation392.15
Mean Deviation133,075,691
Median753,000
Standard Deviation283,897,889
Sample Variance80598T
Range1.1B
R-Value(0.42)
Mean Square Error70857.7T
R-Squared0.18
Significance0.10
Slope(25,261,100)
Total Sum of Squares1208970.2T

Plus Stock Based Compensation History

2025486.5 K
2024512.1 K
2023569 K
2021606 K
2020247 K
2019127 K
2018355 K

Other Fundumenentals of Plus Therapeutics

Stock Based Compensation To Revenue

Plus Therapeutics Stock Based Compensation component correlations

Total Assets
Total Stockholder Equity
Net Debt
Total Liab
Total Current Assets
Retained Earnings
Net Receivables
Short Term Debt
Common Stock
Current Deferred Revenue
Accounts Payable
Intangible Assets
Good Will
Net Tangible Assets
Long Term Debt
Long Term Debt Total
Capital Surpluse
Property Plant Equipment
Net Invested Capital
Net Working Capital
Capital Stock
Total Assets
0.470.210.850.860.090.70.160.620.340.450.490.58-0.20.510.56-0.58-0.250.69-0.240.35
Total Stockholder Equity
0.47-0.150.00.37-0.050.090.050.330.190.210.180.280.380.00.05-0.080.110.480.10.42
Net Debt
0.21-0.150.26-0.250.180.270.40.33-0.37-0.050.790.45-0.440.180.28-0.310.080.46-0.68-0.08
Total Liab
0.850.00.260.810.080.710.140.510.280.470.40.45-0.40.520.55-0.56-0.290.43-0.330.11
Total Current Assets
0.860.37-0.250.810.050.65-0.040.40.510.470.090.33-0.080.480.47-0.48-0.350.390.040.28
Retained Earnings
0.09-0.050.180.080.050.45-0.30.190.48-0.810.460.73-0.20.790.81-0.8-0.550.6-0.420.12
Net Receivables
0.70.090.270.710.650.450.00.370.230.060.550.61-0.240.790.79-0.78-0.590.58-0.330.1
Short Term Debt
0.160.050.40.14-0.04-0.30.0-0.14-0.290.350.21-0.09-0.41-0.4-0.310.170.630.08-0.33-0.22
Common Stock
0.620.330.330.510.40.190.37-0.140.040.140.610.60.170.490.54-0.47-0.150.59-0.290.29
Current Deferred Revenue
0.340.19-0.370.280.510.480.23-0.290.04-0.19-0.20.33-0.050.460.45-0.45-0.370.28-0.170.08
Accounts Payable
0.450.21-0.050.470.47-0.810.060.350.14-0.19-0.18-0.350.05-0.38-0.370.370.3-0.230.14-0.06
Intangible Assets
0.490.180.790.40.090.460.550.210.61-0.2-0.180.8-0.30.540.64-0.64-0.210.8-0.60.25
Good Will
0.580.280.450.450.330.730.61-0.090.60.33-0.350.8-0.330.790.86-0.84-0.420.88-0.540.25
Net Tangible Assets
-0.20.38-0.44-0.4-0.08-0.2-0.24-0.410.17-0.050.05-0.3-0.33-0.19-0.220.320.06-0.260.340.09
Long Term Debt
0.510.00.180.520.480.790.79-0.40.490.46-0.380.540.79-0.190.99-0.92-0.80.67-0.340.18
Long Term Debt Total
0.560.050.280.550.470.810.79-0.310.540.45-0.370.640.86-0.220.99-0.95-0.740.75-0.460.21
Capital Surpluse
-0.58-0.08-0.31-0.56-0.48-0.8-0.780.17-0.47-0.450.37-0.64-0.840.32-0.92-0.950.62-0.790.44-0.25
Property Plant Equipment
-0.250.110.08-0.29-0.35-0.55-0.590.63-0.15-0.370.3-0.21-0.420.06-0.8-0.740.62-0.290.1-0.2
Net Invested Capital
0.690.480.460.430.390.60.580.080.590.28-0.230.80.88-0.260.670.75-0.79-0.29-0.370.44
Net Working Capital
-0.240.1-0.68-0.330.04-0.42-0.33-0.33-0.29-0.170.14-0.6-0.540.34-0.34-0.460.440.1-0.370.25
Capital Stock
0.350.42-0.080.110.280.120.1-0.220.290.08-0.060.250.250.090.180.21-0.25-0.20.440.25
Click cells to compare fundamentals

About Plus Therapeutics Financial Statements

Plus Therapeutics investors use historical fundamental indicators, such as Plus Therapeutics' Stock Based Compensation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Plus Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Stock Based Compensation512.1 K486.5 K
Stock Based Compensation To Revenue 0.12  0.13 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Plus Stock Analysis

When running Plus Therapeutics' price analysis, check to measure Plus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Plus Therapeutics is operating at the current time. Most of Plus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Plus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Plus Therapeutics' price. Additionally, you may evaluate how the addition of Plus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY